当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.

A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.

Abstract：

:Numerous allelic variants identified in the familial breast cancer and DNA repair genes BRCA1 and BRCA2 are of unknown impact on protein function or clinical relevance, referred to as unclassified variants (UCV). Lymphocytes from pathogenic BRCA1/2 mutation carriers exhibit an increased level of chromosomal damage after irradiation. We established a radiation assay for the discrimination of pathogenic BRCA2 variants versus controls based on the level of chromosomal damage upon irradiation (p < 0.001). As a consequence, lymphocytes from UCV carriers could be separated into two distinct groups with normal or diminished DNA double strand break repair capacity. Our results suggested that all five UCV tested were benign and that one family carried a putative mutation in an as yet undetected DNA-repair gene. Thus, our test may serve as a valuable tool that aids the classification of BRCA2 UCV, but very likely also of BRCA1 UCV or aberrations in other genes involved in the DNA-repair system.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Becker AA,Graeser MK,Landwehr C,Hilger T,Baus W,Wappenschmidt B,Meindl A,Weber RG,Schmutzler RK

doi

10.1007/s10549-012-2119-0

subject

Has Abstract

pub_date

2012-08-01 00:00:00

pages

167-75

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

135

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

    abstract：:Since our previous findings had indicated that the androgenic steroid medroxyprogesterone acetate (MPA) exerts potent inhibitory effects on 7,12-dimethylbenz(a)anthracene (DMBA)-induced tumor growth, we have studied the effect of low doses of MPA released from Depo-Provera and from 50:50 poly[DL-lactide-co-glycolide] ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01961245

    authors： Li S,Lepage M,Mérand Y,Bélanger A,Labrie F

    更新日期：1992-01-01 00:00:00

  • Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure.

    abstract：BACKGROUND:The Z0011 trial initiated a paradigm shift in the axillary treatment of breast cancer patients with a positive sentinel lymph node biopsy (SLNB), disregarding patients with a positive ultrasound-guided lymph node biopsy (UGLNB). We examined whether relevant differences exist between these patients to determi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4342-1

    authors： Verheuvel NC,Voogd AC,Tjan-Heijnen VCG,Siesling S,Roumen RMH

    更新日期：2017-10-01 00:00:00

  • Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.

    abstract：:Docetaxel is primarily metabolized by CYP3A4 and susceptible to alterations in clearance by CYP3A4 inhibition and induction. Imatinib is a CYP3A4 inhibitor. A phase I study of docetaxel and imatinib in metastatic breast cancer (MBC) was conducted to test the hypothesis that imatinib decreased docetaxel clearance. Doce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1413-6

    authors： Connolly RM,Rudek MA,Garrett-Mayer E,Jeter SC,Donehower MG,Wright LA,Zhao M,Fetting JH,Emens LA,Stearns V,Davidson NE,Baker SD,Wolff AC

    更新日期：2011-05-01 00:00:00

  • Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.

    abstract：:Epidermal growth factor receptor (EGFr) levels were analyzed in 140 primary breast cancer specimens by immunohistochemical assay (ICA), competitive binding assay (BA), or enzyme immunoassay (EIA). Thirty-nine of 118 specimens (33.1%) were scored as positive by ICA, 30 of 116 (25.9%; cut-off level 10 fmol/mg protein) b...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666582

    authors： Iwase H,Kobayashi S,Itoh Y,Kuzushima T,Yamashita H,Iwata H,Naito A,Yamashita T,Itoh K,Masaoka A

    更新日期：1993-12-01 00:00:00

  • SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.

    abstract：:It is unclear which patients with breast cancer benefit from anthracycline-based neoadjuvant chemotherapy and whether taxanes increase survival. Hsp70 and serpinB3 inhibit a lysosomal cell death pathway induced in anthracycline and taxane treated cells, which may be critical for breast cancer cell survival. Thus we ev...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1625-9

    authors： Collie-Duguid ES,Sweeney K,Stewart KN,Miller ID,Smyth E,Heys SD

    更新日期：2012-04-01 00:00:00

  • Antibodies to 46-kDa retinal antigen in a patient with breast carcinoma and cancer-associated retinopathy.

    abstract：:Cancer-associated retinopathy (CAR) is a rare paraneoplastic syndrome usually associated with small-cell lung carcinoma and serum autoantibodies against recovering. We report the breast cancer woman with visual impairments and electrophysiological abnormalities characteristic of CAR. Her serum contained high-titer ant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9721-6

    authors： Ejma M,Misiuk-Hojło M,Gorczyca WA,Podemski R,Szymaniec S,Kuropatwa M,Rogozińska-Szczepka J,Bartnik W

    更新日期：2008-07-01 00:00:00

  • Estradiol and progesterone receptors in breast cancer: prognostic value after relapse.

    abstract：:The prognostic significance of estradiol (ER) and progesterone receptors (PgR) for survival from relapse has been studied in two groups of breast cancer patients: group 1, 35 patients in whom receptor levels were measured at the time of mastectomy; group II, 49 patients in whom receptor levels were measured at the tim...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805988

    authors： Bonneterre J,Horner D,Peyrat JP,Vandewalle B,Cambier L,Demaille A

    更新日期：1985-01-01 00:00:00

  • Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).

    abstract：:The aim of this study was to compare the effects on health-related quality of life (HRQOL) of two treatment regimens in the TEX trial during 9 month from random assignment, with emphasis on the 2- and 9-months assessments. A total of 287 patients were randomized to treatment in 3-week cycles with either epirubicin plu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-010-1084-8

    authors： Svensson H,Einbeigi Z,Johansson H,Hatschek T,Brandberg Y

    更新日期：2010-10-01 00:00:00

  • Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.

    abstract：:The concept of cancer cells being hierarchically organized and arising from their own progenitor stem cells will have important implications on cancer therapy. If this hypothesis were to be true then the paucity of estrogen receptors in stem cells as well as their inherent drug resistance mechanisms pose a challenge t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0619-3

    authors： Resetkova E,Reis-Filho JS,Jain RK,Mehta R,Thorat MA,Nakshatri H,Badve S

    更新日期：2010-08-01 00:00:00

  • Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.

    abstract：:Multiple adjuvant regimens are used for HER2+ breast cancer, but experience in routine practice is not reported. We evaluated whether oncologists' perceptions of these regimens matches clinical experience. We surveyed Wisconsin medical oncologists throughout the state regarding factors impacting selection of TCH (doce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1862-y

    authors： Rocque G,Onitilo A,Engel J,Pettke E,Boshoven A,Kim K,Rishi S,Waack B,Wisinski KB,Tevaarwerk A,Burkard ME

    更新日期：2012-01-01 00:00:00

  • Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

    abstract：PURPOSE:In our microarray analysis we observed that Seven-in-Absentia Homolog 2 (SIAH2) levels were low in estrogen receptor (ER) positive breast tumors of patients resistant to first-line tamoxifen therapy. The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0125-z

    authors： Jansen MP,Ruigrok-Ritstier K,Dorssers LC,van Staveren IL,Look MP,Meijer-van Gelder ME,Sieuwerts AM,Helleman J,Sleijfer S,Klijn JG,Foekens JA,Berns EM

    更新日期：2009-07-01 00:00:00

  • Health-related quality of life before and after a breast cancer diagnosis.

    abstract：:While many reports describe health-related quality of life (QOL) among breast cancer survivors, few compare QOL before and after diagnosis and whether changes in QOL substantially differ from changes experienced by all women during aging. QOL was examined in a cohort of female residents of Beaver Dam, Wisconsin, aged ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9653-1

    authors： Trentham-Dietz A,Sprague BL,Klein R,Klein BE,Cruickshanks KJ,Fryback DG,Hampton JM

    更新日期：2008-05-01 00:00:00

  • Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis.

    abstract：:Progression of breast cancer from an estrogen-dependent, slowly growing tumor amenable to tamoxifen treatment to an aggressive, metastatic, estrogen-independent phenotype has been mimicked by the transfection of MCF-7 breast carcinoma cells with fibroblast growth factors 1 or 4. FGF-transfected cells are aggressively ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806082

    authors： McLeskey SW,Zhang L,Kharbanda S,Kurebayashi J,Lippman ME,Dickson RB,Kern FG

    更新日期：1996-01-01 00:00:00

  • Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice.

    abstract：:Based on our previous findings that medroxyprogesterone acetate (MPA) significantly suppressed the formation of preneoplastic mammary hyperplastic alveolar nodules in mice, and that this suppression persisted for some time, we studied the effects of different schedules of MPA treatment on spontaneous mammary tumorigen...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805741

    authors： Nagasawa H,Aoki M,Sakagami N,Ishida M

    更新日期：1988-09-01 00:00:00

  • Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

    abstract：:Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated w...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-010-1257-5

    authors： Amadori D,Silvestrini R,De Lena M,Boccardo F,Rocca A,Scarpi E,Schittulli F,Brandi M,Maltoni R,Serra P,Ponzone R,Biglia N,Gianni L,Tienghi A,Valerio MR,Bonginelli P,Amaducci L,Faedi M,Baldini E,Paradiso A

    更新日期：2011-02-01 00:00:00

  • Photodynamic therapy as an effective therapeutic approach in MAME models of inflammatory breast cancer.

    abstract：:Photodynamic therapy (PDT) is a minimally invasive, FDA-approved therapy for treatment of endobronchial and esophageal cancers that are accessible to light. Inflammatory breast cancer (IBC) is an aggressive and highly metastatic form of breast cancer that spreads to dermal lymphatics, a site that would be accessible t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3618-6

    authors： Aggarwal N,Santiago AM,Kessel D,Sloane BF

    更新日期：2015-11-01 00:00:00

  • The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger.

    abstract：:PIN1, an isomerase that causes conformational changes in proteins, plays an important role in mammary epithelial cell growth both physiologically and pathologically. Thus, genetic variants in the PIN1 gene may alter protein function and cancer risk. We have previously demonstrated an association between a PIN1 promote...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0682-9

    authors： Han CH,Lu J,Wei Q,Bondy ML,Brewster AM,Yu TK,Buchholz TA,Arun BK,Wang LE

    更新日期：2010-07-01 00:00:00

  • Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.

    abstract：:Obesity is associated with an increased risk of breast cancer (BC) and poorer outcome. We assessed the impact of body mass index (BMI) on pathological complete response (pCR), disease-free (DFS), and overall survival (OS), according to BC subtypes in patients with primary BC treated with neoadjuvant chemotherapy. 8,87...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3287-5

    authors： Fontanella C,Lederer B,Gade S,Vanoppen M,Blohmer JU,Costa SD,Denkert C,Eidtmann H,Gerber B,Hanusch C,Hilfrich J,Huober J,Schneeweiss A,Paepke S,Jackisch C,Mehta K,Nekljudova V,Untch M,Neven P,von Minckwitz G,Loibl

    更新日期：2015-02-01 00:00:00

  • Increased hematopoietic progenitor cell maintenance in long-term bone marrow cultures containing minimal numbers of contaminating breast cancer cells.

    abstract：:The maintenance of hematopoietic progenitor cells as assayed in the mixed colony (CFU-GEMM) assay in human long-term bone marrow cultures was compared between normal allogeneic marrow transplantation donor collections and those from candidates for high-dose therapy and autologous bone marrow transplantation (ABMT). To...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005732531318

    authors： Mann SL,Joshi SS,Crouse DA,Armitage JO,Kessinger A,Weisenburger DD,Vaughan WP,Sharp JG

    更新日期：1997-06-01 00:00:00

  • Cytogenetic evaluation of 20 sporadic breast cancer patients and their first degree relatives.

    abstract：:Many genetic abnormalities disclosed even in somatic cells like peripheral blood lymphocytes may mark footprint(s) of malignancy(ies). The present cytogenetic study on peripheral blood lymphocytes of sporadic breast cancer patients (n = 20) and their first degree relatives (n = 39) reports abnormalities of chromosomes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005951125574

    authors： Trivedi AH,Roy SK,Bhachech SH,Patel RK,Dalal AA,Bhatavdekar JM,Patel DD

    更新日期：1998-03-01 00:00:00

  • Factors associated with the incompliance with mammogram screening among individuals with a family history of breast cancer or ovarian cancer.

    abstract：OBJECTIVE:The national guidelines recommend more intensive screening for breast cancer for women with a family history of breast or ovarian cancer. Using the data from the 2000 National Health Interview Survey (NHIS), we examined factors related to the underuse of mammogram in this population. METHOD:The study subject...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9298-5

    authors： Wu H,Zhu K,Jatoi I,Shah M,Shriver CD,Potter J

    更新日期：2007-03-01 00:00:00

  • Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.

    abstract：:The regulation of gene expression by steroid hormones plays an important role in the normal development and function of many organs, as well in the pathogenesis of endocrine-related cancers. Previous experiments have shown that many kallikrein genes are under steroid hormone regulation in breast cancer cell lines. We ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9312-y

    authors： Paliouras M,Diamandis EP

    更新日期：2007-03-01 00:00:00

  • Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.

    abstract：:The biological subtype of breast cancer influences the selection of systemic therapy. Distinction between luminal A and B cancers depends on consistent assessment of Ki-67, but substantial intra-observer and inter-observer variability exists when immunohistochemistry (IHC) is used. We compared RT-qPCR with IHC in the ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3835-7

    authors： Wirtz RM,Sihto H,Isola J,Heikkilä P,Kellokumpu-Lehtinen PL,Auvinen P,Turpeenniemi-Hujanen T,Jyrkkiö S,Lakis S,Schlombs K,Laible M,Weber S,Eidt S,Sahin U,Joensuu H

    更新日期：2016-06-01 00:00:00

  • What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer?

    abstract：:The epidermal growth factor receptor (EGFR) is expressed in benign and malignant breast epithelium. The EGFR, when mutated or over-expressed in the presence of its ligand, is transforming in other tissues or cell types. It is therefore of major interest in the pathogenesis of human breast cancer to understand the role...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666176

    authors： Harris AL

    更新日期：1994-01-01 00:00:00

  • Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.

    abstract：:The present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7/Arom 14, which was stably transfected with the cDNA of huma...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1141-3

    authors： Nukatsuka M,Saito H,Nakagawa F,Abe M,Uchida J,Shibata J,Matsuo K,Noguchi S,Kiniwa M

    更新日期：2011-07-01 00:00:00

  • Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.

    abstract：PURPOSE:To investigate the discordance between original and central laboratories in estrogen receptor (ER) status, in tumors originally deemed to be ER-negative, and in HER2 status in a diverse population-based sample. METHODS:In a follow-up study of 1785 women with Stage I-III breast cancer diagnosed between 2005 and...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4061-z

    authors： Griggs JJ,Hamilton AS,Schwartz KL,Zhao W,Abrahamse PH,Thomas DG,Jorns JM,Jewell R,Saber ME,Haque R,Katz SJ

    更新日期：2017-01-01 00:00:00

  • Rho proteins and cancer.

    abstract：:The Rho family of GTPases has been intensively studied for their roles in signal transduction processes leading to cytoskeletal-dependent responses, including cell migration and phagocytosis. In addition, they are important regulators of cell cycle progression and affect the expression of a number of genes, including ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/B:BREA.0000018423.47497.c6

    authors： Ridley AJ

    更新日期：2004-03-01 00:00:00

  • Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue.

    abstract：:The purpose of the present study was to characterize primitive epithelial progenitor populations present in adult normal human mammary tissue using a combination of flow cytometry and in vitro colony assay procedures. Three types of human breast epithelial cell (HBEC) progenitors were identified: luminal-restricted, m...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1010615124301

    authors： Stingl J,Eaves CJ,Zandieh I,Emerman JT

    更新日期：2001-05-01 00:00:00

  • The impact of diabetes on survival following breast cancer.

    abstract：PURPOSE:It has been suggested that type 2 diabetes may affect breast cancer prognosis, possibly due to increased diabetes-related comorbidity, or direct effects of insulin resistance and/or hyperinsulinemia. The purpose of this study was to examine the impact of diabetes on survival following breast cancer. METHODS:Us...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9654-0

    authors： Lipscombe LL,Goodwin PJ,Zinman B,McLaughlin JR,Hux JE

    更新日期：2008-05-01 00:00:00

  • Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.

    abstract：:Abnormal translation of mRNAs frequently occurring during carcinogenesis is among the mechanisms that can affect the expression of proteins involved in tumor development and progression. Eukaryotic initiation factor eIF4E is a key regulator of translation of many cancer-related transcripts and its expression is altere...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2671-2

    authors： Heikkinen T,Korpela T,Fagerholm R,Khan S,Aittomäki K,Heikkilä P,Blomqvist C,Carpén O,Nevanlinna H

    更新日期：2013-08-01 00:00:00